AlivaMab Biologics
- Company typePrivate
- Founded2018
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
AlivaMab Biologics firmographics
Firmographics- Name
- AlivaMab Biologics
- Legal name
- AlivaMab Biologics, LLC
- Website
- https://alivamab.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
AlivaMab Biologics industry classification
Industry- Product category
- Antibody Drug Discovery Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industry
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where AlivaMab Biologics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
AlivaMab Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Fee-for-Service Antibody Discovery: Contract research services providing end-to-end antibody drug discovery and engineering. Partners engage AMB for discovery and engineering services using the AlivaMab Mouse platform on a fee-for-service basis. Now available milestone- and royalty-free for service partners.
- Platform Licensing: Non-exclusive licensing of AlivaMab Mouse technology to pharmaceutical and biotechnology companies for their own internal antibody discovery programs. Multiple companies have licensed the technology including global pharmaceutical companies.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
AlivaMab Biologics product offering
Product offeringCore offering
AlivaMab Biologics provides end-to-end contract research services for the discovery and engineering of fully human therapeutic antibodies, anchored by its patented AlivaMab Mouse transgenic platform and complemented by proprietary immunization, screening, and engineering methodologies. The company offers partners customizable capability modules (discovery, engineering, bispecifics, CARs, developability) on a fee-for-service basis, now available milestone- and royalty-free, with additional non-exclusive licensing of the AlivaMab Mouse technology to pharmaceutical and biotechnology companies for internal programs.
Product overview
AlivaMab Biologics provides a fully integrated platform for biologics drug discovery and engineering through modular, customizable capability modules. The core technology is the AlivaMab Mouse transgenic platform, which includes multiple strains (AlivaMab Mouse-NGX, AlivaMab Mouse-SDX) for generating human therapeutic antibodies. These are complemented by proprietary methodologies including AMMPD Immunizations, Fit-for-Purpose Screening, Immune Repertoire Display, and Bispecific Formats. The platform includes supporting capabilities such as Alivalign software for in silico analysis, CAR Engineering, Developability Assessment, and NGS-Based Hit Expansion. The company offers these as discrete capability modules that partners can select individually or engage across the full spectrum for end-to-end biologics discovery programs.
Differentiator
Problem solved
Functional benefit
Products and services
- Antibody Discovery Services
- Antibody Engineering Services
- AlivaMab Mouse Platform Licensing
- AlivaMab Mouse-NGX
- Milestone- and Royalty-Free Discovery Service
- T-Cell Engager and Multispecific Engineering Services
- Developability Assessment Service
Companies that use AlivaMab Biologics
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
AlivaMab Biologics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
AlivaMab Biologics partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core, major and strategic.
- Ablexis, LLCcoreSister company that creates and licenses the AlivaMab Mouse technology. Both companies share leadership under Larry Green (CEO of both). AlivaMab Biologics provides integrated discovery services using Ablexis technology. Together they form the primary antibody discovery platform offering.
- Janssen Research & Development, LLCmajorMulti-target discovery agreement where ADS provides expertise and capabilities to generate and deliver therapeutic antibody candidates to Janssen for further evaluation. Part of Johnson & Johnson.
- Teva PharmaceuticalsmajorMulti-target agreement for generating diverse panels of fully human antibodies for multiple therapeutic programs. Leverages ADS discovery platform including AMMPD immunization technologies.
- Tanabe Research Laboratories USAmajorDiscovery partnership with subsidiary of Mitsubishi Tanabe Pharma Corporation. ADS provides expertise and capabilities using AlivaMab Mouse platform for integrated antibody drug discovery collaboration.
- Almirall, S.A.majorMulti-target licensing agreement between Ablexis and Almirall for use of AlivaMab Mouse technology for discovery, development and commercialization of antibodies. ADS conducts the drug discovery research for Almirall focusing on dermatological conditions.
- Berkeley Lights, Inc.strategicCollaboration to identify diverse panel of anti-SARS-CoV-2 human antibodies. Combined Ablexis AlivaMab Mouse, ADS immunization expertise, and Berkeley Lights Beacon platform for single cell selection and functional screening.
- IGM BiosciencesmajorRapidly expanding list of partners utilizing ADS discovery and engineering capabilities for antibody drug development.
Scale indicators8 records
Recent moves9 records
Expansion highlights6 records
AlivaMab Biologics competitors and assessment
Company assessmentBroad incumbents
- Lonza Biologics: Lonza provides integrated biologics development and manufacturing services, including antibody-related discovery and cell line development. It is a broad incumbent offering overlapping capabilities as part of a much larger service portfolio.
- WuXi Biologics: WuXi Biologics is a large global CRO/CDMO offering end-to-end biologics discovery, development, and manufacturing services including antibody discovery. It competes broadly on integrated service offerings and has substantially greater scale than AlivaMab Biologics.
- GenScript ProBio: GenScript ProBio offers antibody discovery, development, and manufacturing services as part of a broader life sciences services portfolio. It is a broad incumbent serving pharma and biotech customers with bundled biologics offerings.
Direct peers
- Adimab: Adimab provides yeast display-based antibody discovery and engineering services to pharma and biotech. It is a direct competitor offering an alternative display-based platform for fully human therapeutic antibody generation with similar fee-for-service and partnership models.
- AbCellera Biologics: AbCellera is a leading antibody discovery platform combining single-cell screening, AI, and a proprietary technology stack for fully human antibody discovery. It serves the same pharma/biotech customer base and is a direct competitor in antibody discovery CRO services.
- Trianni (Alloy Therapeutics): Trianni, now part of Alloy Therapeutics, licenses transgenic mouse platforms (Trianni Mouse) for fully human antibody discovery. It is a direct competitor offering alternative transgenic technology to pharma for internal and partnered antibody programs.
- OmniAb: OmniAb operates a discovery platform combining proprietary transgenic animals (OmniRat, OmniMouse, OmniChicken) and AI for therapeutic antibody discovery. It is a direct competitor in the transgenic-platform antibody discovery space and has overlapping pharma customers.
- Kymab (Sanofi): Kymab operated the IntelliSelect transgenic mouse antibody discovery platform before being acquired by Sanofi in 2021. It was a direct peer offering competing transgenic antibody technology to pharma partners prior to acquisition.
Emerging players
- Harbour BioMed: Harbour BioMed operates the H2L2 transgenic mouse platform for fully human antibody discovery and develops its own pipeline. It is an emerging player with overlapping platform technology and a partial overlap in target customer base.
Others
- Ablexis: Ablexis is the sister company that owns and licenses the AlivaMab Mouse transgenic platform under shared CEO Larry Green. It is a closely related entity rather than a competitor, but is directly comparable as a platform licensor in the antibody discovery space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
AlivaMab Biologics social profiles
Digital presenceAlivaMab Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
AlivaMab Biologics leadership team
Management profileNumber of profiles
Profiles6 records
AlivaMab Biologics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AlivaMab Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AlivaMab Biologics
What does AlivaMab Biologics do?
AlivaMab Biologics provides end-to-end contract research services for the discovery and engineering of fully human therapeutic antibodies, anchored by its patented AlivaMab Mouse transgenic platform and complemented by proprietary immunization, screening, and engineering methodologies. The company offers partners customizable capability modules (discovery, engineering, bispecifics, CARs, developability) on a fee-for-service basis, now available milestone- and royalty-free, with additional non-exclusive licensing of the AlivaMab Mouse technology to pharmaceutical and biotechnology companies for internal programs.
Is AlivaMab Biologics a public or private company?
AlivaMab Biologics is a private company. It is classified as private equity controlled and is currently operating.
When was AlivaMab Biologics founded?
AlivaMab Biologics was founded in 2018. It employs 11 to 50 people.
Where is AlivaMab Biologics based?
AlivaMab Biologics is headquartered in San Diego, United States, in the North America region.
How does AlivaMab Biologics make money?
Two revenue lines are on record. Fee-for-Service Antibody Discovery is the primary driver. The others are platform Licensing.
Who are AlivaMab Biologics's main competitors?
Broad incumbents on record are Lonza Biologics, WuXi Biologics and GenScript ProBio. Direct peers are Adimab, AbCellera Biologics, Trianni (Alloy Therapeutics), OmniAb and Kymab (Sanofi). Harbour BioMed is listed as an emerging player. Ablexis is listed as an others.
Does AlivaMab Biologics have an API?
No public API is recorded for AlivaMab Biologics.
What industry is AlivaMab Biologics in?
AlivaMab Biologics's product category is Antibody Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 5417 and its SIC code is 8731.